Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Indium 111-radiolabelled OTSA 101 (Primary) ; OTSA 101-Y 90 (Primary)
- Indications Synovial sarcoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors OncoTherapy Science
Most Recent Events
- 31 Jan 2024 Status changed from recruiting to discontinued.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2023 to 1 Mar 2024.
- 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Mar 2024.